Our science
Human biology first. We start every program with evidence from people, not from a molecule looking for a home.
Our research approach
A Baxtra program is only allowed to advance when it can answer four questions. What human evidence links this target to this disease? Which patients carry that biology? What measurement will show the drug is engaging the target in those patients? And what would make us stop?
We call this the four-gate model, and it is applied at target selection, candidate selection, end of Phase 1 and end of Phase 2 by a review board that includes external scientists and patient representatives. Roughly 60% of proposed targets never clear the first gate.
Platforms
Four research engines
Targeted protein degradation
Our LYSOTAG and molecular-glue libraries remove disease-driving proteins rather than inhibiting them, opening targets long considered undruggable — transcription factors, scaffolding proteins and mutant oncoproteins with no catalytic pocket.
14 programs · Lead assets: BX-231 (oncology), BX-556 (immunology)
Precision immunology
Tissue-resident immune profiling at single-cell resolution lets us treat the immune pathway that is actually active in a given patient, rather than the average patient in a diagnosis code.
11 programs · Lead assets: BX-417 (lupus nephritis), BX-118 (IBD)
Targeted delivery
Antibody–drug conjugates and ligand-directed nanoparticles that concentrate payload in diseased tissue. Our linker chemistry is designed for stability in circulation and rapid release inside the target cell.
9 programs · Lead asset: BX-770 (HER2-low breast cancer)
mRNA & genetic medicines
Self-amplifying mRNA for vaccines and AAV-delivered gene therapy for monogenic disease, with a proprietary capping chemistry that reduces innate immune activation.
7 programs · Lead assets: BX-VX3 (RSV/hMPV), BX-G12 (Fabry disease)
Human genetics and real-world data
The Baxtra Human Evidence Platform links genomic, proteomic and longitudinal clinical records from 1.6 million consented participants across ten cohorts on four continents. Targets with human genetic support are roughly twice as likely to survive Phase 2, and we weight our portfolio accordingly.
All participant data is de-identified, held under an independent data access committee, and never sold. Participants can withdraw consent at any time and have their samples destroyed.
Translational medicine
Translational medicine sits between discovery and clinical development and owns the question of whether a molecule does in people what it did in the lab. Every Baxtra first-in-human protocol includes a target-engagement readout — receptor occupancy, degradation percentage, CSF biomarker shift or tissue transcriptomics — before any efficacy endpoint is considered.
- Dose selection driven by exposure–response modelling, not maximum tolerated dose alone
- Adaptive Phase 1b/2a designs with pre-specified futility rules
- Central biomarker laboratories in Cambridge and Basel with harmonised assays
- Digital endpoints (wearable gait, speech, actigraphy) validated against clinical scales
Research ethics
Every human study Baxtra sponsors is reviewed by an independent ethics committee or institutional review board before a single participant is enrolled, and we follow the principles of the Declaration of Helsinki and ICH Good Clinical Practice everywhere we operate — including where local law is less strict.
Animal research
Some safety questions cannot yet be answered without animal studies. We apply the 3Rs (replacement, reduction, refinement), require a documented non-animal alternatives assessment for every protocol, and publish annual animal use numbers in our responsibility report.
Informed consent
Consent documents are written to a plain-language reading standard and tested with patient advisers. Participants receive a summary of the study results in lay language when the trial completes.
Trials in lower-income settings
We only run a trial in a country where we intend to seek registration and supply the medicine, and we commit to post-trial access for participants who benefited.
Conflicts of interest
Payments to healthcare professionals and organisations are disclosed annually. Investigators may not hold equity in Baxtra while running a Baxtra-sponsored study.
Publications & data sharing
We register every interventional trial before the first participant is enrolled and post results within 12 months of completion, whatever the outcome. Qualified external researchers can request patient-level data through our independent review panel.
| Publication | Journal | Date |
|---|---|---|
| Complete renal response with BX-417 in active lupus nephritis: the AURORA-3 trial | New England Journal of Medicine | Aug 2026 |
| Selective degradation of mutant KRAS G12D by BX-231 in pancreatic models | Nature | May 2026 |
| Neurofilament light as a response biomarker in ALS: pooled analysis | The Lancet Neurology | Mar 2026 |
| Single-cell atlas of inflamed intestinal mucosa in refractory Crohn’s disease | Cell | Jan 2026 |
| Safety and immunogenicity of a self-amplifying RSV/hMPV vaccine in older adults | JAMA | Nov 2025 |